Immunotherapy plus chemo before surgery for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have limited-stage small cell lung cancer (confirmed by biopsy and imaging, and can be removed with surgery)
- Your daily activities are mostly normal (ECOG score 0 or 1)
- Your liver, kidneys, and blood work are in good shape
- You have not had any prior treatment for this lung cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination treatment for early-stage small-cell lung cancer. It compares giving immunotherapy drugs (PD-1/PD-L1 inhibitors) along with chemotherapy before surgery versus chemotherapy alone, to see if the combination helps shrink tumors more effectively and improves outcomes.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery, followed by surgery and radiation, is effective for limited-stage small cell lung cancer. The goal is to see if this approach helps control the cancer better than standard treatment alone.
This trial tests whether giving an immunotherapy drug called toripalimab together with chemotherapy after lung cancer surgery can help prevent small cell lung cancer from coming back. It is for people who had surgery to remove lung cancer and were found to have small cell lung cancer in the removed tissue.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.